New Epogen and Aranesp Injection Codes

Why This Topic Matters

The page helps readers recognize that a CMS code update affects ESRD injection claims and that associated claim documentation and site-of-service considerations are part of the reporting process.

Article Sections

1. Switchover to new Epogen and Aranesp Q codes

   Introduces the CMS update and the shift away from older billing codes for these ESRD-related injections. It frames the change as a Medicare claims issue.

2. Claim reporting details for Aranesp

   Summarizes the types of claim information CMS expects to accompany Aranesp reporting in the context described by the article. The section focuses on documentation elements and claim form placement at a broad level.

3. Coverage and site-of-service notes

   Covers general CMS remarks about coverage criteria and how administration setting is addressed for ESRD patients. It also notes the separate physician office billing context referenced in the article.